Characteristic and Management of Ameloblastoma In Oral And Maxillofacial Surgery At Hasan Sadikin General Hospital: Retrospective Study
DOI:
https://doi.org/10.32553/ijmbs.v6i10.2609Keywords:
Ameloblastoma, Epidemiology, Odontogenic, TumourAbstract
Introduction
Ameloblastoma is common benign epithelial tumor of odontogenic origin. The presentation of ameloblastoma is unique as it locally aggressive tumor with high recurrence rate if not treated adequately. This study aimed to conduct retrospective study to analyze the characteristics and management of ameloblastoma in patient Oral and Maxillofacial Surgery at Hasan Sadikin General Hospital between periods of January 2020 – December 2020.
Material and Method
This was a retrospective, descriptive feature of all histopathologically diagnosed ameloblastoma during 2020. We took data from each patient such as demographic (gender, age), radiological features, histopatholoical diagnosis, location, management, defect and reconstruction of ameloblastoma.
Result
A total 23 patients were diagnosed with conventional ameloblastoma, including 11 plexiform (48%), ten follicular (43%), and two mixed types of plexiform-follicular (9%). Among them, 6 (21%) patients were treated conservatively (Enucleation and dredging) and 17 patients were treated radically with segmental resection in 9 (39%) patients, hemimandibulectomy in 5 (22%) patients, marginal resection in 2 (9%) patients, and hemimaxillectomy in one (4%) patient.
Conclusion
The common characteristic of ameloblastoma is follicular and plexiform ameloblastoma with the most predilection location in mandible region and the peak of incidence in third decades of life. Radical treatment is more often used to reduce recurrence rates, whereas conservative measures are normally preserved in children and adolescent.
Keywords: Ameloblastoma, Epidemiology, Odontogenic, Tumour
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Journal of Medical and Biomedical Studies
This work is licensed under a Creative Commons Attribution 4.0 International License.